Document is current
Any future updates will be listed below
-
Authors
Matsubara, Nobuaki
Miura, Yuji
Nishiyama, Hiroyuki
Taoka, Rikiya
Kojima, Takahiro
Shimizu, Nobuaki
Hwang, Jason
Ote, Tatsuya
Oyama, Ryo
Toyoizumi, Kiichiro
Mukhopadhyay, Sutapa
Triantos, Spyros
Deprince, Kris
Loriot, Yohann
-
Funding
Funding for this research was provided by:
Janssen Pharmaceutical K.K.
- License Information
-
More Information
Article History
Received: 22 May 2024
Accepted: 2 July 2024
First Online: 17 July 2024
Declarations
:
: Nobuaki Matsubara has received grants or contracts from Janssen Pharmaceutical K.K., MSD K.K., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Astellas Pharma Inc., Bayer AG, Amgen K.K., Takeda Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Eisai Co. Ltd., Roche/Genentech, Seagen, Novartis Pharma K.K., and AbbVie Inc.; consulting fees from Sanofi K.K., Janssen Pharmaceutical K.K., AstraZeneca K.K., Eli Lilly Japan K.K., Amgen K.K., Seagen, and Pfizer Japan Inc.; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Sanofi K.K.. Yuji Miura has received grants or contracts from MSD and Ono Pharmaceutical Co., Ltd.; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Takeda Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Eisai Co. Ltd., Ono Pharmaceutical Co., Ltd., and MSD. Hiroyuki Nishiyama has received grants or contracts from Ono Pharmaceutical Co., Ltd., and Chugai Pharmaceutical Co., Ltd.; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from MSD, Astellas Pharma Inc., Merck Biopharma Co. Ltd., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., and Nippon Fine Chemical Co., Ltd..; other financial or non-financial interests from Bayer Yakuhin, Ltd Rikiya Taoka and Nobuaki Shimizu report no conflicts of interest. Takahiro Kojima has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astellas Pharma Inc. Jason Hwang reports employment and employee stock ownership from Janssen Pharmaceutical K.K.; Tatsuya Ote reports employment from Janssen Pharmaceutical K.K., and employee stock ownership from Janssen Pharmaceutical K.K., and Johnson & Johnson. Ryo Oyama reports employment and employee stock ownership from Janssen Pharmaceutical K.K. Kiichiro Toyoizumi reports employment from Janssen Pharmaceutical K.K., and employee stock ownership from Johnson & Johnson. Sutapa Mukhopadhyay, Spyros Triantos, and Kris Deprince report employment from Janssen Research & Development, and employee stock ownership from Johnson & Johnson. Yohann Loriot has received grants or contracts from Janssen Oncology, MSD Oncology, AstraZeneca, Exelixis, Incyte, Pfizer Japan Inc., Sanofi K.K., Seagen, Astellas Pharma Inc., Gilead Sciences Inc., Merck KGaA, Taiho Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Roche, and Tyra Biosciences; consulting fees from Janssen Pharmaceutical Co. Ltd., Astellas Pharma Inc., Roche, AstraZeneca, MSD Oncology, Seagen, Bristol-Myers Squibb, Taiho Pharmaceutical Co., Ltd., Loxo/Lilly, Pfizer/EMD Serono, Merck KGaA, Gilead Sciences, Pfizer Japan Inc., Roche, MSD Oncology; support for attending meetings and/or travel from Astellas Pharma, Janssen Oncology, Roche, MSD Oncology, AstraZeneca, and Seagen.
